Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group Limited has announced that its GLP-1/GIP receptor dual-biased agonist polypeptide injection, SYH2069, has received approval from the U.S. FDA to conduct clinical trials in the United States. This product, which is poised to be China’s first of its kind, shows promise in weight management and glycemic control for type 2 diabetes, demonstrating superior efficacy and safety in preclinical studies. The approval marks a significant step for CSPC in enhancing its position in the global pharmaceutical market, particularly in the field of metabolic diseases.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated company operating in the pharmaceutical industry. The company focuses on developing innovative drugs and therapeutic solutions, with a market emphasis on metabolic diseases and weight management.
Average Trading Volume: 135,253,583
Technical Sentiment Signal: Buy
Current Market Cap: HK$88B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.